Slide 1: Cover letter to stock exchanges
November 9, 2022 BSE Limited, National Stock Exchange of India Limited, P J Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Bandra (East), Mumbai – 400 001. Mumbai 400051. BSE Scrip Code : 524735 NSE Symbol : HIKAL Dear Sir/ Madam, Subject: Results Presentation of the Company for the qua
Slide 2: Results Presentation – Q2 FY23
Results Presentation – Q2 FY23
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Hikal Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and
Slide 4: Executive Chairman’s Message
Executive Chairman’s Message “Hikal has recorded a steady performance in Q2 in line with earlier guidance of a sequential recovery as we continue to move towards resuming our strong growth trajectory. In Q2, we achieved the highest-ever quarterly revenue in the history of Hikal, backed by strong dem
Slide 5: Quarterly Financials Highlights
Quarterly Financials Highlights
Slide 6: Q2 FY23 Revenue, EBITDA, PAT, EPS
Gradual Recovery in Q2 - expect to see continuous improvement in revenues and margins Revenue – Q2 FY23 EBITDA – Q2 FY23 EBITDA Margin – Q2 FY23 Rs. 559 Crore Rs. 70 Crore 12.5% YoY QoQ YoY QoQ YoY QoQ 19% 48% -23% 207% -690 bps 650 bps PAT – Q2 FY23 EPS – Q2 FY23 Rs. 25 Crore Rs 2.01 YoY QoQ YoY Qo
Slide 7: Quarterly Performance Highlights
Quarterly Performance Highlights Revenue +47% 559 Performance Highlights 469 379 • Revenue recorded an increase of 19% YoY and stood at Rs. 559 Cr • Crop Protection business has demonstrated strong rebound on account of industry tailwinds Q2FY22 Q1FY23 Q2FY23 • Sequential recovery in revenue and mar
Slide 8: Quarterly Performance Highlights – Pharmaceuticals
Quarterly Performance Highlights – Pharmaceuticals Revenue +29% Pharmaceuticals - Performance Highlights 280 290 • Revenue recorded an increase of 4% YoY and stood at INR 290 Cr 224 • Demand slowdown as well as inflation pressures in the end market continue • EBIT stood at Rs. 11 Cr • Significant in
Slide 9: Quarterly Performance Highlights – Crop Protection
Quarterly Performance Highlights – Crop Protection Revenue +75% Crop Protection - Performance Highlights 269 • Revenue recorded an increase of 42% YoY • Robust demand from customers in both own products and 190 CDMO segments 154 • EBIT stood at Rs. 35 Crore • Higher input costs of raw materials, sol
Slide 10: Quarterly Financial Highlights
Quarterly Financial Highlights Consolidated Revenue Consolidated EBITDA Consolidated PAT 559 94 44 45 515 91 502 469 70 379 61 25 21 23 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 -9 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Rs. Crore © Hikal Limited
Slide 11: Quarterly Segmental Highlights
Quarterly Segmental Highlights Pharmaceuticals Revenue Crop Protection Revenue 308 290 280 268 269 246 224 190 194 154 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Pharmaceuticals EBIT Crop Protection EBIT 37 36 38 34 35 30 11 12 10 -8 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q2FY
Slide 12: Consolidated Profit & Loss – Q2 FY23
Consolidated Profit & Loss – Q2 FY23 Particulars (Rs. Crore) Q2 FY23 Q2 FY22 Y-o-Y Q1 FY23 Q-o-Q Net Sales 559 469 19% 379 48% Expenditure 489 378 356 EBITDA 70 91 -23% 23 208% Margin 12.5% 19.4% 6.0% Other Income 1 1 3 Depreciation 27 24 27 Finance Costs 11 8 11 PBT 33 60 -45% (12) NA Tax 8 16 (3)
Slide 13: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (Rs. Crore) Sep-22 Mar-22 Equities & Liabilities (Rs. Crore) Sep-22 Mar-22 Total Non Current Assets 1,333 1,249 Shareholders Fund 1,080 1,068 Property, Plant and Equipment 878 815 Share Capital 25 25 Capital work in Progress 306 285 Other Equity 1,055 1,043 Right to
Slide 14: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. Crore) Half Year ended 30-Sep-22 Half Year ended 30-Sep-21 Profit before tax 21 128 Adjustments 70 67 Operating Profit Before Working Capital Changes 91 195 Change in operating assets and liabilities 2 28 Cash generated from operations 93 223 Income
Slide 15: Half-Yearly Financials Highlights
Half-Yearly Financials Highlights
Slide 16: Financial Highlights – Half-Yearly
Financial Highlights – Half-Yearly Revenue – H1 FY23 EBITDA – H1 FY23 EBITDA Margin – H1 FY23 Rs. 938 Crore Rs. 92 Crore 9.9% YoY YoY YoY 1% -50% -1030 bps PAT – H1 FY23 EPS – H1 FY23 Rs. 16 Crore Rs 1.29 YoY YoY -83% -83% © Hikal Limited
Slide 17: Half-Yearly Performance Highlights
Half-Yearly Performance Highlights Revenue EBITDA PAT 926 938 187 95 92 16 H1FY22 H1FY23 H1FY22 H1FY23 H1FY22 H1FY23 Pharmaceuticals Division Crop Protection Division 554 423 514 372 Revenue Revenue H1FY22 H1FY23 H1FY22 H1FY23 86 66 46 EBIT EBIT 2 Rs. Crore H1FY22 H1FY23 H1FY22 H1FY23 © Hikal Limite
Slide 18: Sales Break-Up
Sales Break-Up Pharmaceuticals Revenue Break-Up Crop Protection Revenue Break-Up CDMO Own products 41.2% 35.5% 44.5% 69.0% 65.1% 76.7% 58.8% 64.5% 55.5% 31.0% 34.9% 23.3% FY21 FY22 H1FY23 FY21 FY22 H1FY23 © Hikal Limited
Slide 19: Annual Financials Highlights
Annual Financials Highlights
Slide 20: Financial Highlights - Annual
Financial Highlights - Annual Revenue – FY22 EBITDA – FY22 EBITDA Margin – FY22 Rs. 1,943 Crore Rs. 341 Crore 17.5% FY18-22 FY18-22 YoY YoY YoY CAGR CAGR 13% 5% -124bps 11% 9% PAT – FY22 EPS – FY22 Rs. 161 Crore Rs 13.02 FY18-22 FY18-22 YoY YoY CAGR CAGR 21% 21% 20% 20% © Hikal Limited
Slide 21: Annual Performance Highlights
Annual Performance Highlights Revenue EBITDA PAT +13% +5% +21% 1,943 323 341 161 1,720 133 FY21 FY22 FY21 FY22 FY21 FY22 Pharmaceuticals Division Crop Protection Division +7% +23% 1,060 1,130 813 661 Revenue Revenue FY21 FY22 FY21 FY22 +11% -11% 170 115 151 103 EBIT EBIT Rs. Crore FY21 FY22 FY21 FY2
Slide 22: Yearly Financial Highlights
Yearly Financial Highlights Consolidated Revenue Consolidated EBITDA Consolidated PAT +9% +11% 1,943 341 161 323 1,720 298 +20% 1,590 133 1,507 273 242 1,300 103 84 77 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 Rs. Crore © Hikal Limited
Slide 23: Sales Break-Up
Sales Break-Up Pharmaceuticals Revenue Break-Up Crop Protection Revenue Break-Up CDMO Own products 41.2% 44.5% 54.0% 69.0% 76.7% 75.7% 58.8% 55.5% 46.0% 31.0% 23.3% 24.3% FY20 FY21 FY22 FY20 FY21 FY22 © Hikal Limited
Slide 24: Yearly Segmental Highlights
Yearly Segmental Highlights Pharmaceuticals Revenue Crop Protection Revenue +11% +10% 1,130 813 1,060 939 887 651 661 620 753 547 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 Pharmaceuticals EBIT Crop Protection EBIT +7% +11% 170 112 115 151 100 103 129 128 87 99 FY18 FY19 FY20 FY21 FY22 FY18 F
Slide 25: Consolidated Profit & Loss – Full Year
Consolidated Profit & Loss – Full Year Particulars (Rs. Crore) FY22 FY21 Y-o-Y Net Sales 1,943 1,720 13% Expenditure 1,602 1,397 EBITDA 341 323 3% Margin 17.5% 18.8% Other Income 5 5 Depreciation 96 85 Finance Costs 31 36 Exceptional Item - - PBT 219 206 6% Tax 58 73 Net Profit 161 133 21% Margin 8.
Slide 26: Ratio Analysis
Ratio Analysis ROE ROCE 16.1% 15.2% 15.0% 16.2% 12.8% 15.2% 12.5% 14.5% 12.0% 10.7% FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 Net Debt / Equity Net Debt / EBITDA 0.91 2.51 0.83 2.11 2.13 0.71 0.61 1.78 1.81 0.59 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 © Hikal Limited
Slide 27: Annual Dividend Payout
Annual Dividend Payout Dividend Payout 14% 24% 22% 18% 19% 17% 20% 19% 19% 12% including DDT 13.02 EPS DPS 10.80 8.36 6.85 6.27 5.70 5.18 3.28 3.35 2.05 2.00 1.20 1.60 1.00 1.00 1.20 1.20 1.20 0.90 0.50 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 The above dividend is based on Face Value of Rs
Slide 28: Contact Us
Contact Us Company : Investor Relations Advisors : Hikal Limited Strategic Growth Advisors Pvt. Ltd. CIN: L24200MH1988PTC048028 CIN: U74140MH2010PTC204285 Mr. Kuldeep Jain Mr. Jigar Kavaiya / Mr. Aakash Mehta +91-9920602034 / +91-9819178243 Kuldeep_jain@hikal.com jigar.kavaiya@sgapl.net / aakash.meh
Slide 29: HIKAL
HIKAL